Laboratoire de Pharmacologie, Institut Claudius Regaud, IUCT-Oncopole et Centre de Recherches en Cancérologie de Toulouse, Inserm UMR1037, Université Paul Sabatier, Toulouse, France.
Laboratoire de Pharmacologie et Toxicologie, CHU de Saint-Etienne, Saint-Etienne, France.
Br J Clin Pharmacol. 2023 Feb;89(2):762-772. doi: 10.1111/bcp.15536. Epub 2022 Oct 3.
Determining dihydropyrimidine dehydrogenase (DPD) activity by measuring patient's uracil (U) plasma concentration is mandatory before fluoropyrimidine (FP) administration in France. In this study, we aimed to refine the pre-analytical recommendations for determining U and dihydrouracil (UH ) concentrations, as they are essential in reliable DPD-deficiency testing.
U and UH concentrations were collected from 14 hospital laboratories. Stability in whole blood and plasma after centrifugation, the type of anticoagulant and long-term plasma storage were evaluated. The variation induced by time and temperature was calculated and compared to an acceptability range of ±20%. Inter-occasion variability (IOV) of U and UH was assessed in 573 patients double sampled for DPD-deficiency testing.
Storage of blood samples before centrifugation at room temperature (RT) should not exceed 1 h, whereas cold (+4°C) storage maintains the stability of uracil after 5 hours. For patients correctly double sampled, IOV of U reached 22.4% for U (SD = 17.9%, range = 0-99%). Notably, 17% of them were assigned with a different phenotype (normal or DPD-deficient) based on the analysis of their two samples. For those having at least one non-compliant sample, this percentage increased up to 33.8%. The moment of blood collection did not affect the DPD phenotyping result.
Caution should be taken when interpreting U concentrations if the time before centrifugation exceeds 1 hour at RT, since it rises significantly afterwards. Not respecting the pre-analytical conditions for DPD phenotyping increases the risk of DPD status misclassification.
在法国,氟嘧啶(FP)给药前必须通过测量患者尿嘧啶(U)血浆浓度来确定二氢嘧啶脱氢酶(DPD)活性。本研究旨在完善 U 和二氢尿嘧啶(UH)浓度的分析前建议,因为它们是可靠的 DPD 缺乏检测所必需的。
从 14 家医院实验室收集 U 和 UH 浓度。评估了离心后全血和血浆中的稳定性、抗凝剂的类型以及长期血浆储存。计算并比较了时间和温度引起的变化与可接受范围±20%。在 573 例 DPD 缺乏检测的患者中,对 U 和 UH 的间变(IOV)进行了双样本评估。
在室温(RT)下离心前储存血液样本不应超过 1 小时,而低温(+4°C)储存可在 5 小时后保持 U 稳定。对于正确双采样的患者,U 的 IOV 达到 22.4%(U 的 SD=17.9%,范围 0-99%)。值得注意的是,根据对其两个样本的分析,其中 17%的患者被分配了不同的表型(正常或 DPD 缺乏)。对于那些至少有一个不合规样本的患者,这一比例上升至 33.8%。采血时间不影响 DPD 表型的结果。
如果在 RT 下离心前超过 1 小时,则应谨慎解释 U 浓度,因为之后 U 浓度会显著升高。不遵守 DPD 表型分析的分析前条件会增加 DPD 状态分类错误的风险。